Video

Dr. Abida on using PARP inhibitors in mCRPC patients with non-BRCA1/2 HRR gene alterations

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses whether he would recommend FDA-approved PARP inhibitors (ie, olaparib, rucaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes other than BRCA1/2. In the pivotal PROFOUND trial of olaparib in mCRPC, researchers examined PARP inhibition in patients with at least 1 of 15 different genes with a direct or indirect role in HRR: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L. In the video, Abida explains how the specific mutation type determines whether or not he feels comfortable recommending a PARP inhibitor for a patient.

      © 2025 MJH Life Sciences

      All rights reserved.